Sofosbuvir vs. Combination of Pegylated Interferon and Ribavirin; How Much Shall Pay for Iranian Patients?

Author(s):
Mohamad Amin PourhoseingholiMohamad Amin Pourhoseingholi1, Sara AshtariSara Ashtari1, Seyed Moayed AlavianSeyed Moayed AlavianSeyed Moayed Alavian ORCID2,*
1Gastroenterology and Liver Diseases Research Center, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
2Middle East Liver Diseases Center (MELD), Tehran, IR Iran

Hepatitis Monthly:Vol. 14, issue 11; 25540
Published online:Nov 22, 2014
Article type:Editorial
Received:Nov 21, 2014
Accepted:Nov 22, 2014
How to Cite:Pourhoseingholi MA, Ashtari S, Alavian SM. Sofosbuvir vs. Combination of Pegylated Interferon and Ribavirin; How Much Shall Pay for Iranian Patients?. Hepat Mon. 2014;14(11):25540. doi: https://doi.org/10.5812/hepatmon.25540

Abstract

Full Text

Full text is available in PDF

Similar Articles

30
Sep
2010

Which is the IDEAL Peginterferon for Hepatitis C: A Meta-Analysis of both Pegylated Interferons in the Treatment of HCV-Infected Patients

Frank Tacke

Tacke F. Which is the IDEAL Peginterferon for Hepatitis C: A Meta-Analysis of both Pegylated Interferons in the Treatment of HCV-Infected Patients. Hepat Mon. 2010;10(3):. doi:

30
Sep
2010

Efficacy of Peginterferon Alpha-2a vs. 2b for the Treatment of Chronic HCV: Interpretation of Results and Future Prospects

Hossein Khedmat

Khedmat H. Efficacy of Peginterferon Alpha-2a vs. 2b for the Treatment of Chronic HCV: Interpretation of Results and Future Prospects. Hepat Mon. 2010;10(3):. doi:

8
Mar
2017

Comments on “The Efficacy of 12 Weeks of Sofosbuvir, Daclatasvir, and Ribavirin in Treating Hepatitis C Patients with Cirrhosis, Genotypes 1 and 3”

Babak Sayad,
Fatemeh Norooznezhad,
Alireza Farokhi

Sayad B, Norooznezhad F, Farokhi A. Comments on “The Efficacy of 12 Weeks of Sofosbuvir, Daclatasvir, and Ribavirin in Treating Hepatitis C Patients with Cirrhosis, Genotypes 1 and 3”. Hepat Mon. 2017;17(3):e58720. doi: https://doi.org/10.5812/hepatmon.46588

30
Jun
2004

How to manage side effects of interferon alpha therapy in Chronic Hepatitis C?

Kamran Bagheri Lankarani

Lankarani K. How to manage side effects of interferon alpha therapy in Chronic Hepatitis C?. Hepat Mon. 2004;4(6):. doi:

31
Mar
2006

Efficacy and safety of Interferon-alpha (PDferon B®) and Ribavirin Combination Therapy in patients with Chronic Hepatitis C in Iran

Seyed Moayed Alavian,
Masoud Ahmadzad Asl,
maryam keshvari,
Bita Behnava,
bashir hajibeigi

Alavian SM, Ahmadzad Asl M, keshvari M, Behnava B, hajibeigi B. Efficacy and safety of Interferon-alpha (PDferon B®) and Ribavirin Combination Therapy in patients with Chronic Hepatitis C in Iran. Hepat Mon. 2006;6(1):e92946. doi:


Crossmark
Crossmark
Checking
Share on
Cited by
Metrics

Ordering Reprints

Articles are published under the Creative Commons license stated on each article. No permission or royalty fee is required for uses permitted by that license. CCC handles optional bulk and customized reprint orders. Any quotation covers production and delivery services only, not copyright permission. > Request Reprints from CCC 

Search Relations

Author(s):

Related Articles